Inpharma 1391 - 14 Jun 2003

■ Zotepine significantly improved chorea in apatient with Huntington’s disease (HD), according toresearchers from Austria. They report the case of a32-year-old woman with genetically confirmed HDwho presented with severe chorea that wassignificantly disabling. She was subsequently treatedwith oral zotepine 400 mg/day, as her chorea did notrespond to conventional treatments. Improvements inmotor activity and functional capacity were observedwithin the first week of treatment, and the woman wasable to resume her activities of daily living. Theimprovement in her function was maintained at thelast reported follow-up (9 weeks). The researchersconclude that atypical neuroleptics may be thetreatment of choice in Huntington’s chorea.Bonelli RM, et al. Zotepine in Huntington’s disease. HumanPsychopharmacology: Clinical and Experimental 18: 227-229, Apr2003 800925993

1

Inpharma 14 Jun 2003 No. 13911173-8324/10/1391-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved